Clinical trial
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
NCT02362503 is registered in ClinicalTrials.gov with ViiV Healthcare as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
- Lead sponsor
- ViiV Healthcare
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- February 23, 2015
- Completion date
- October 22, 2026
- Enrollment
- 371 (actual)
- Sites
- 139
Conditions
As the registry lists them; a condition with its own page is linked.